Hypertension
Conditions
Interventions
losartan / HCTZ group
high-dose angiotensin II receptor antagonist group
Sponsors
Vascular Care Network (VCN) Kamanza study group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with essential hypertension, who have been previously treated with antihypertensive drugs including standard- dose ARB for more than 3 months, however, whose blood pressure has not been adequately controlled (systolic blood pressure >140 mmHg and/or diastolic blood pressure >90mmHg) 2) Men and women aged 20 to 85 years at the time of the first visit. 3) Outpatients 4) Patients who fully understand the study procedures explained to them using explanatory notes and have given written informed consent to participate in the study
Exclusion criteria
Exclusion criteria: 1) Patients under treatment with diuretics 2) Patients with office systolic blood pressure ≥ 180mmHg or office diastolic blood pressure ≥ 110mmHg 3) Patients with malignant hypertension 4) Patients who have stroke, myocardial infarction or other critical vascular complications that required hospitalization within 6 months prior to informed consent 5) Patients with liver dysfunction (ALT [GOT] and/or AST [GPT] over three times the normal value) 6) Patients with renal failure (serum creatinine ≥2.0 mg/dL) 7) Patients with a gout attack or hyperuricemia (≥8.0mg/dL) 8) Pregnant or breast feeding female patients, including one trying to conceive pregnancy during the planned study period 9) Patients with uncontrolled arrhythmia 10) Patients with severe valvular disease including mitral stenosis and incompetence of aortic valve 11) Patients with cardiac insufficiency (NYHA grade III or IV) 12) Patients with a history of hypersensitivity to ingredients of losartan potassium 13) Patients with a history of hypersensitivity to thiazide or thiazide-like diuretics 14) Patients who are considered not eligible for the study by the attending doctor due to medical reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change and % change in blood pressure after 3months of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| - Change and % change in serum uric acid and serum blood glucose level after 3, 6 and 12 months of treatment. - Change and % change in blood pressure after 6 and 12 months of treatment. - Change and % change in HbA1c, microalbuminuria and BNP after 6 and 12 months of treatment. - Safety throughout the treatment period | — |
Countries
Japan
Contacts
Public ContactHiroshi Fujita
Vascular Care Network (VCN) Kamanza study group secretariat Vascular Care Network (VCN) Kamanza study group secretariat
Outcome results
None listed